These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23311989)

  • 1. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
    Luong ML; Husain S; Rotstein C
    Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
    Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic effects of aspergillosis management in high-risk patients.
    Leather H
    Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
    Garbino J; Schnetzler G; Roberts C
    Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
    Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
    Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
    Selleslag D; Vogelaers D; Marbaix S
    Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
    Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
    Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
    Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
    J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.
    Turner SJ; Senol E; Kara A; Al-Badriyeh D; Dinleyici EC; Kong DC
    BMC Infect Dis; 2013 Nov; 13():560. PubMed ID: 24279677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients].
    Romá-Sánchez E; Poveda-Andrés JL; García-Pellicer J; Salavert-Lletí M; Jarque-Ramos I
    Farm Hosp; 2008; 32(1):7-17. PubMed ID: 18426697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
    Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
    Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.